Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 31.43 | 20.72 | 26.34 | 33.40 | 11.90 | 26.34 | 24.34 | 56.17 | 15.43 | 56.60 | — | 50.71 | 20.87 | 21.60 | 11.45 | 21.89 | 14.16 | 24.83 | 22.56 | 16.74 | 16.06 |
| — | -21.4% | +8.2% | -40.5% | -22.9% | -53.5% | — | +10.8% | -26.0% | +162.1% | — | +131.7% | +47.4% | -13.0% | -49.3% | +30.8% | -11.8% | -67.0% | +2.6% | -19.6% | -13.3% | |
| P/S Ratio | 6.57 | 4.90 | 5.55 | 4.49 | 4.00 | 4.12 | 5.17 | 3.89 | 5.13 | 5.04 | 5.12 | 4.74 | 5.24 | 4.27 | 5.33 | 5.17 | 4.56 | 4.95 | 5.34 | 4.64 | 4.52 |
| — | +18.9% | +7.4% | +15.5% | -22.1% | -18.2% | +1.1% | -18.1% | -1.9% | +18.1% | -3.9% | -8.3% | +14.9% | -13.9% | -0.3% | +11.5% | +0.9% | -7.9% | -12.8% | -8.4% | -22.4% | |
| P/B Ratio | 28.00 | 16.85 | 20.83 | 20.53 | 15.90 | 20.34 | 27.15 | 24.04 | 23.20 | 28.53 | 30.35 | 24.96 | 18.89 | 17.58 | 24.32 | 38.67 | 33.20 | 54.01 | 145.46 | 18.97 | 14.75 |
| — | -17.1% | -23.3% | -14.6% | -31.5% | -28.7% | -10.5% | -3.7% | +22.8% | +62.3% | +24.8% | -35.5% | -43.1% | -67.4% | -83.3% | +103.8% | +125.0% | +217.3% | +839.2% | +32.7% | +8.0% | |
| P/FCF | 29.80 | 14.12 | 32.40 | 46.24 | 9.00 | 19.76 | 43.00 | 8.03 | 13.17 | 19.03 | 83.00 | 134.54 | 14.39 | 7.77 | 45.16 | 15.33 | 10.76 | 19.40 | 16.87 | 12.60 | 13.93 |
| — | -28.6% | -24.7% | +476.0% | -31.7% | +3.9% | -48.2% | -94.0% | -8.4% | +145.0% | +83.8% | +777.8% | +33.8% | -60.0% | +167.6% | +21.6% | -22.7% | -3.5% | -9.5% | -25.8% | +20.3% | |
| EV / EBITDA | 18.11 | 17.46 | 15.65 | 11.00 | 12.92 | 12.50 | 21.16 | 12.77 | 16.41 | 16.80 | 21.62 | 19.73 | 14.60 | 10.23 | 14.19 | 13.76 | 10.76 | 13.48 | 12.24 | 12.07 | 11.37 |
| — | +39.7% | -26.1% | -13.9% | -21.3% | -25.6% | -2.1% | -35.3% | +12.4% | +64.2% | +52.4% | +43.4% | +35.7% | -24.1% | +15.9% | +14.0% | -5.4% | -45.5% | -15.0% | -13.7% | -12.8% | |
| EV / EBIT | 26.87 | 17.46 | 21.59 | 25.75 | 10.75 | 21.88 | 20.13 | 30.97 | 14.57 | 34.70 | 68.36 | 31.26 | 15.74 | 15.48 | 10.04 | 19.98 | 13.63 | 21.78 | 20.76 | 15.45 | 14.98 |
| — | -20.2% | +7.2% | -16.8% | -26.2% | -36.9% | -70.5% | -0.9% | -7.4% | +124.2% | +580.6% | +56.5% | +15.5% | -28.9% | -51.6% | +29.3% | -9.0% | -56.1% | +3.9% | -15.8% | -14.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.8% | 72.0% | 68.2% | 81.9% | 67.8% | 67.2% | 63.6% | 65.7% | 61.1% | 61.4% | 57.0% | 62.0% | 73.8% | 74.0% | 71.8% | 74.5% | 76.1% | 77.1% | 75.0% | 74.9% | 76.0% |
| — | +7.3% | +7.2% | +24.6% | +10.9% | +9.3% | +11.5% | +6.0% | -17.3% | -17.1% | -20.6% | -16.7% | -3.0% | -4.0% | -4.2% | -0.6% | +0.2% | +2.9% | +0.3% | -1.3% | +0.4% | |
| Operating Margin | 29.1% | 35.0% | 30.9% | 39.8% | 26.4% | 28.8% | 14.5% | 25.4% | 24.1% | 22.8% | 13.3% | 15.5% | 29.3% | 38.4% | 31.5% | 32.6% | 40.0% | 33.0% | 40.1% | 33.7% | 35.5% |
| — | +21.2% | +114.0% | +56.6% | +9.8% | +26.7% | +8.6% | +64.0% | -17.8% | -40.8% | -57.7% | -52.4% | -26.8% | +16.4% | -21.5% | -3.1% | +12.8% | +160.1% | +11.1% | +11.2% | -7.1% | |
| Net Margin | 21.0% | 23.6% | 21.1% | 13.5% | 33.7% | 15.6% | 21.2% | 6.9% | 33.3% | 8.9% | -1.5% | 9.4% | 25.1% | 19.7% | 46.5% | 23.6% | 32.2% | 20.0% | 23.7% | 27.7% | 28.1% |
| — | +51.2% | -0.6% | +95.2% | +1.1% | +75.6% | +1499.1% | -26.3% | +32.8% | -54.9% | -103.3% | -60.4% | -22.2% | -1.2% | +96.7% | -14.8% | +14.7% | +180.9% | -15.2% | +13.9% | -10.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 106.1% | 22.8% | 20.4% | 14.6% | 37.7% | 21.0% | 28.6% | 9.4% | 42.1% | 13.6% | -2.0% | 11.0% | 24.0% | 22.7% | 63.1% | 44.2% | 70.6% | 79.0% | 38.8% | 25.5% | 22.9% |
| — | +8.3% | -28.8% | +55.9% | -10.3% | +54.1% | +1525.8% | -15.3% | +75.6% | -40.1% | -103.2% | -75.0% | -66.0% | -71.2% | +62.7% | +73.6% | +208.4% | +1396.3% | +120.7% | +60.6% | +22.4% | |
| ROA | 8.5% | 2.5% | 2.0% | 1.5% | 3.6% | 1.6% | 1.9% | 0.7% | 3.1% | 0.8% | -0.1% | 0.8% | 1.9% | 1.5% | 3.7% | 2.5% | 3.5% | 2.2% | 2.5% | 3.0% | 3.0% |
| — | +56.3% | +4.1% | +114.9% | +16.0% | +99.1% | +1705.9% | -16.0% | +62.7% | -47.3% | -103.2% | -67.4% | -45.1% | -30.7% | +50.6% | -16.7% | +15.4% | +193.0% | -6.5% | +18.9% | -3.1% | |
| ROIC | 14.8% | 4.8% | 3.7% | 5.4% | 3.4% | 3.6% | 1.6% | 3.1% | 2.6% | 2.4% | 1.2% | 2.0% | 4.5% | 5.8% | 4.1% | 4.9% | 6.0% | 5.0% | 5.9% | 5.2% | 5.2% |
| — | +34.0% | +126.7% | +76.9% | +32.1% | +48.8% | +30.3% | +50.2% | -42.2% | -58.3% | -69.6% | -58.6% | -25.0% | +15.4% | -30.9% | -6.0% | +14.6% | +184.3% | +33.7% | +26.0% | +2.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.31 | 4.90 | 6.24 | 6.31 | 5.67 | 7.57 | 9.24 | 10.23 | 8.02 | 10.57 | 12.75 | 10.37 | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 |
| — | -35.2% | -32.5% | -38.3% | -29.3% | -28.4% | -27.5% | -1.4% | +1.6% | +16.5% | +10.7% | -2.5% | -25.5% | -39.9% | -71.4% | +114.0% | +131.7% | +279.8% | +1049.0% | +41.8% | +46.2% | |
| Debt / EBITDA | 3.45 | 16.65 | 15.16 | 10.76 | 14.24 | 14.10 | 22.37 | 16.21 | 17.54 | 18.93 | 26.79 | 24.37 | 20.74 | 17.19 | 21.83 | 12.40 | 11.07 | 12.16 | 11.03 | 10.55 | 11.64 |
| — | +18.1% | -32.2% | -33.6% | -18.8% | -25.5% | -16.5% | -33.5% | -15.4% | +10.1% | +22.7% | +96.6% | +87.4% | +41.4% | +97.9% | +17.5% | -4.9% | -37.6% | +0.2% | -7.8% | +13.9% | |
| Current Ratio | 1.14 | 1.37 | 1.26 | 1.14 | 1.28 | 1.31 | 1.17 | 1.26 | 1.32 | 1.26 | 1.42 | 1.65 | 2.86 | 2.77 | 3.14 | 1.41 | 1.68 | 1.53 | 1.44 | 1.59 | 1.64 |
| — | +5.0% | +7.8% | -9.3% | -2.9% | +3.3% | -17.7% | -23.8% | -53.9% | -54.4% | -54.8% | +16.6% | +70.3% | +81.0% | +118.8% | -11.1% | +2.2% | +16.9% | -13.2% | -12.3% | -27.9% | |
| Quick Ratio | 0.90 | 1.13 | 1.01 | 0.90 | 0.99 | 0.98 | 0.88 | 0.95 | 0.96 | 0.89 | 0.98 | 1.13 | 2.56 | 2.48 | 2.79 | 1.10 | 1.35 | 1.17 | 1.09 | 1.26 | 1.36 |
| — | +14.5% | +15.4% | -6.1% | +3.5% | +10.2% | -10.3% | -15.7% | -62.7% | -64.0% | -64.9% | +2.9% | +90.3% | +111.9% | +155.0% | -12.4% | -1.2% | +13.9% | -18.5% | -15.2% | -27.5% | |
| Interest Coverage | 4.26 | 5.11 | 4.17 | 3.32 | 6.72 | 3.21 | 3.73 | 2.05 | 5.00 | 1.98 | 0.92 | 2.04 | 3.57 | 3.15 | 7.34 | 5.21 | 7.50 | 5.67 | 6.68 | 7.36 | 8.28 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMGN stock.
Amgen Inc.'s current P/E is 31.4x. The average P/E over the last 4 quarters is 23.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Amgen Inc.'s current operating margin is 29.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amgen Inc.'s business trajectory between earnings reports.